OnKure Therapeutics

Company snapshot

OnKure is committed to the discovery and development of best-in-class precision medicines that target biologically validated drivers of #cancer.

• 8 active pipeline program(s) linked via ClinicalTrials.gov.
• 7 US patent(s) indexed to this assignee profile.
• 8 trial update(s) in the last 12 months.

Public regulatory, clinical, patent, and corporate records for OnKure Therapeutics. Not investment advice.

• Peer + 0 momentum

  Bristol Myers Squibb

  TA overlap score 28

• Peer + 0 momentum

  Alaunos Therapeutics

  TA overlap score 26.8

• Peer + 0 momentum

  Prime Medicine

  TA overlap score 23.4

Recent activity

Latest pipeline, patent, and corporate events for OnKure Therapeutics.

1. Jun 8, 2026 Clinical update

   OKI-219-101 — Phase 1

2. Jun 8, 2026 Clinical update

   Low Dose REN001 — Phase 1

3. May 23, 2026 Clinical update

   REN001 — Phase 3

4. May 23, 2026 Clinical update

   Mavodelpar — Phase 2

5. May 23, 2026 Clinical update

   OKI-179 + binimetinib — Phase 2

View all clinical trial activity →

• What is OnKure Therapeutics?

  OnKure Therapeutics is a pharma organization headquartered in Boulder, USA. It trades on NYSE under ticker OKUR. Primary therapeutic focus areas include Primary Mitochondrial Myopathy, Advanced Solid Tumors, Advanced Breast Cancer, Fatty Acid Oxidation Disorders, Advanced Solid T

• Is OnKure Therapeutics publicly traded?

  Yes. OnKure Therapeutics is listed with ticker OKUR on NYSE per SEC EDGAR records linked on this profile.

• What drugs does OnKure Therapeutics develop or market?

  We link 4 drug profile(s) where OnKure Therapeutics is an originator or marketer in FDA or regional approval metadata. See the drug portfolio table on https://novapharmanews.com/companies/onkure-therapeutics#company-drugs.

• What are the latest developments for OnKure Therapeutics?

  In the last 12 months our linked public records show 8 trial program update(s) and 0 US patent grant(s) tied to this profile.

• What therapeutic areas does OnKure Therapeutics focus on?

  OnKure Therapeutics focuses on Primary Mitochondrial Myopathy, Advanced Solid Tumors, Advanced Breast Cancer, Fatty Acid Oxidation Disorders based on our analysis of their pipeline programs and drug development activities.